8-K

                                    FORM 8-K


                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): October 24, 2002



                             MEDTOX SCIENTIFIC, INC.
             (Exact name of registrant as specified in its charter)


                                    Delaware
                 (State or other jurisdiction of incorporation)


1-11394                                                  95-3863205
(Commission File Number)                       (IRS Employer Identification No.)


402 West County Road D
St. Paul, Minnesota                                                      55112
(Address of principal executive offices)                              (Zip Code)


                                 (651) 636-7466
              (Registrant's telephone number, including area code)







Item 9.           Regulation FD Disclosure

     On October 24, 2002,  the  company's  CEO  presented to investors at Profit
Journal's Upper Midwest Small-Cap  Conference in Minneapolis,  MN. A copy of the
presentation is attached as Exhibit 99.1.







                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                        MEDTOX Scientific, Inc.




Date:  October 24, 2002                          By:    /s/ Richard J. Braun
                                               Name:    Richard J. Braun
                                              Title:    Chief Executive Officer

EX-99

                                                                    Exhibit 99.1
                             MEDTOX Scientific, Inc.
                                October 24, 2002

Forward-looking  statements  contained in this  presentation  are made under the
Safe Harbor Provision of the Private  Securities  Litigation Reform Act of 1995.
Any such  statements  are  subject to risks and  uncertainties  that could cause
actual results to differ  materially  from those  anticipated.  Such factors are
described  from  time to time in the  company's  Annual  Report on Form 10-K and
other reports filed with the Securities and Exchange Commission.




MEDTOX Scientific, Inc.
Operating Companies

o        Laboratory Services
o        POC Diagnostics

Synergy enhances the dual opportunity
for profitable growth






MEDTOX Scientific, Inc.
Markets

o      Laboratory Services        76%
o      DRUGS OF ABUSE             51%
        o      Workplace
        o      Prison, probation, parole, rehabilitation
o      SPECIALTY TESTING          25%
        o      Pharmaceutical Industry
        o      Pediatric Screening (Lead-filter paper)
        o      Esoteric Clinical (TDM)
        o      Occupational Health






MEDTOX Scientific, Inc.
Markets

o      Laboratory Services 76%
o      DRUGS OF ABUSE (DAU) 51%
        o      Workplace
        o      Prison, probation, parole, rehabilitation
o      SPECIALTY TESTING       25%
        o      Pharmaceutical Industry
        o      Pediatric Screening
        o      Esoteric Clinical (TDM)
        o      Occupational Health

o      POC Diagnostics 24%
o      DRUGS OF ABUSE (DAU) 21%
        o      Workplace
        o      Prison, probation, parole, rehab
        o      Clinical trials
        o      Hospital ER
o      ENVIRONMENTAL/OEM  3%
        o      Agricultural
        o      Biological





MEDTOX Scientific, Inc.
Market Size

o      Laboratory Services
o      $7-$10  billion market
o      Fragmented industry

o      MEDTOX:
        o      Growth in all markets
        o      Technology leadership
        o      Differentiation-value added services






MEDTOX Scientific, Inc.
Market Size

o      Laboratory Services
o      $7-$10  billion market
o      Fragmented industry
o      MEDTOX:
        o      Growth in all markets
        o      Technology
        o      Differentiation

o      POC Diagnostics
o      $1+ billion market
o      15 - 20% market growth
o      MEDTOX:
        o      Proven, patented products
        o      Vertically integrated
        o      Economical, simple to use
        o      47 products FDA cleared







MEDTOX Scientific, Inc.
3rd Quarter 2002 Financial Review

o      Revenue and Gross Margin
        o      8.4% overall Revenue increase from prior-year period
        o      39.3% Overall Gross Margin
        o      61.6% POC Diagnostics Gross Margin
o      Operating Income
        o      $886,000 compared to $1,084,000
o      Net Income
        o      $11,320,000 compared to $790,000
          o        $10.8 million tax benefit in Q3






MEDTOX Scientific, Inc.
Momentum and Opportunity

o      Laboratory Services
o      Operating leverage
o      Margin opportunity
o      Growth Drivers
        o      Clinical trials
        o      Pediatric screening
        o      POC System sales
        o      WebTox (TM)
        o      Cyclical opportunity





MEDTOX Scientific, Inc.
Momentum and Opportunity

o      Laboratory Services
o      Operating leverage
o      Margin opportunity
o      Growth Drivers
        o      Clinical trials
        o      Pediatric screening
        o      POC System sales
        o      WebTox (TM)
        o      Cyclical opportunity

o      POC Diagnostics
o      Highest margins
o      Fastest growing segment
o      Adaptable technology
o      Growth Drivers
        o      New products
        o      New customers
        o      Cardinal Health
        o      Integrated services





MEDTOX Scientific, Inc.

o        Laboratory Services
o        POC Diagnostics

Logistics, Data Management, Integrated Services






MEDTOX Scientific, Inc.
Management

o      Richard Braun - CEO (5)
o      Kevin Wiersma - COO MEDTOX Labs (10)
o      Mitchell Owens - COO POC Diagnostics (14)
o      James Schoonover - Chief Marketing Officer (5)
o      Susan Puskas - VP QA/QC Regulatory Affairs (11)
o      Jennifer Collins - VP Laboratory Director (11)






MEDTOX Scientific, Inc.
Financial Objectives

o      10-20% Annual Revenue Growth
o      40% Laboratory Services Gross Margin
o      60-65% + POC Diagnostics Gross Margin
o      10 - 15% Pretax Margins: Laboratory
o      15 - 20% Pretax Margin: POC






MEDTOX Scientific, Inc.
Summary

o      Strong, established customer relationships
        o      Recurring revenue streams
o      Higher margin business fastest growing
o      Diversified growth into large markets
o      Aggressive but achievable financial objectives
o      Strategy and product development in place to support long-term profitable
       growth